Endourologic Control of Incontinence with GAX Collagen: The LSU Experience

Publisher Website
Google Scholar
Abstract
Extensive experience has been documented in the use of transcystoscopic injectables in a wide variety of urologic situations. Incontinence has been the primary indication for the use of these substances, and clinical trials have met with success. Concern about particle migration has raised doubts about long-term human safety with some substances such as Teflon. Glutaraldehyde cross-linked (GAX) collagen (Contigen; Bard) has been used in several clinical trials. At our institution, more than 100 patients have been treated to date for incontinence, primarily postprostatectomy in men and Type III stress incontinence in women as part of a larger multicenter trial currently being concluded. This substance has demonstrated ease of use, adaptability to office technique under local anesthesia, and high rates of success.

This publication has 3 references indexed in Scilit: